Identical Cardiovalve systems were used to perform the procedures 18 months apart on a high-risk heart patient. Identical Cardiovalve systems were used to perform the procedures 18 months apart on a high-risk heart patient. | | |
|
Researchers tracked the long-term safety, effectiveness and durability of first-generation CoreValve devices in nearly 900 patients. Researchers tracked the long-term safety, effectiveness and durability of first-generation CoreValve devices in nearly 900 patients. | | |
|
Medtronic and Abbott are often seen as rivals in a competitive marketplace, but the two companies are collaborating with a simple goal in mind: improving patient access to high-quality CGM devices. Medtronic and Abbott are often seen as rivals in a competitive marketplace, but the two companies are collaborating with a simple goal in mind: improving patient access to high-quality CGM devices. | | |
|
The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one. The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one. | | |
|
Using a cerebral protection device during TAVR was associated with lower readmission rates, shorter hospital stays—and, yes, a lower risk of patients suffering a major stroke. A team of specialists with Cleveland Clinic shared their new findings in the Journal of the American Heart Association. Using a cerebral protection device during TAVR was associated with lower readmission rates, shorter hospital stays—and, yes, a lower risk of patients suffering a major stroke. A team of specialists with Cleveland Clinic shared their new findings in the Journal of the American Heart Association. | | |
|
Cardiologist Dan Blumenthal, MD, MBA, explains how changes in Medicare payments will greatly impact cardiology in the years ahead. In just a few short years, the business side of cardiology could look substantially different than it does today. Cardiologist Dan Blumenthal, MD, MBA, explains how changes in Medicare payments will greatly impact cardiology in the years ahead. In just a few short years, the business side of cardiology could look substantially different than it does today. | | |
|
Early evidence suggests a new PET imaging agent from California-based Attralus can help evaluate all varieties of systemic cardiac amyloidosis. It has now been granted the FDA's breakthrough therapy designation. Early evidence suggests a new PET imaging agent from California-based Attralus can help evaluate all varieties of systemic cardiac amyloidosis. It has now been granted the FDA's breakthrough therapy designation. | | |
|
The new expert consensus decision pathway replaces a similar document from 2019 and is to be used in conjunction with heart failure guidelines published in 2022 by the ACC, American Heart Association and Heart Failure Society of America. The new expert consensus decision pathway replaces a similar document from 2019 and is to be used in conjunction with heart failure guidelines published in 2022 by the ACC, American Heart Association and Heart Failure Society of America. | | |
|
The new device from Huxley Medical offers care teams a way to monitor patients for signs of sleep apnea while also keeping a close eye on their heart health. The new device from Huxley Medical offers care teams a way to monitor patients for signs of sleep apnea while also keeping a close eye on their heart health. | | |
|
CVRx has now received improved outpatient and inpatient reimbursements for its implantable heart failure device in the last 12 months. The company's president says these updates will help more patients gain access to the Barostim technology. CVRx has now received improved outpatient and inpatient reimbursements for its implantable heart failure device in the last 12 months. The company's president says these updates will help more patients gain access to the Barostim technology. | | |
|
